Small Molecules

7 November 2015

Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies

7 November 2015

Alzheon Announces Initiation of Clinical Studies with ALZ-801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease

7 November 2015

Samumed Begins Enrollment in a Phase II Clinical Trial for the Treatment of Osteoarthritis (OA) of the Knee Using a Novel Wnt Pathway Modulator

7 November 2015

Acetylon’s Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models

7 November 2015

FDA Accepts Amgen’s New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide

6 November 2015

TaiwanJ Pharmaceuticals Gains FDA Approval for Entering Phase 2 Clinical Study on Autoimmune Hepatitis, an Orphan Disease

6 November 2015

U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

5 November 2015

EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients

5 November 2015

CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC)

5 November 2015

NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin

3 November 2015

Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture

3 November 2015

ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

3 November 2015

Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound

3 November 2015

Janssen Submits Application to the EMA to Expand Use of IMBRUVICA® (ibrutinib) in Previously Untreated Chronic Lymphocytic Leukaemia Patients

3 November 2015

Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers

3 November 2015

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143 at the 27th EORTC-NCI-AACR symposium in Boston

3 November 2015

Zosano Pharma Announces Positive Phase 1 Results for Its ZP-Triptan Patch Program for Treatment of Migraine

3 November 2015

MicuRx Reports Positive Top-Line Results From Phase 2 US Clinical Trial For Novel Antibiotic MRX-I

2 November 2015

Theravance Biopharma Submits Investigational New Drug (IND) Application for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

2 November 2015

Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.

2 November 2015

Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation

2 November 2015

AADi Launches Its Phase 2 Registration Trial for ABI-009, a Targeted mTOR Inhibitor, for Patients with Advanced PEComa, a Rare Form of Sarcoma

2 November 2015

Canbex Therapeutics Announces Start of Phase II Trial of VSN16R for Spasticity

31 October 2015

FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon’s Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor

30 October 2015

Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients

30 October 2015

Completion of Phase I Clinical Trial of Novel Syk Inhibitor HMPL-523 for Autoimmune Diseases in Healthy Volunteers

30 October 2015

FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease

30 October 2015

Anacor Pharmaceuticals Announces Top-Line Results From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis

30 October 2015

Celgene’s VIDAZA® (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia

29 October 2015

Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

PD-1 Agonists Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

TL1A Inhibitor Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

FcRn Inhibitors Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis